Price, David http://orcid.org/0000-0002-9728-9992
Hancock, Kerry http://orcid.org/0000-0003-3728-496X
Doan, Joseph
Taher, Sri Wahyu
Muhwa, Chakaya J.
Farouk, Hisham
Beekman, Maarten J. H. I. http://orcid.org/0000-0002-5978-9697
Funding for this research was provided by:
AstraZeneca (NA, NA, NA, NA, NA, NA, NA)
Article History
Received: 28 January 2022
Accepted: 16 August 2022
First Online: 29 September 2022
Competing interests
: D.P. has an advisory board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Viatris, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, and Thermo Fisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Viatris, GlaxoSmithKline, Pfizer, Mundipharma, Novartis, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Viatris, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Viatris, Mundipharma, Novartis, Regeneron Pharmaceuticals, Pfizer, Sanofi Genzyme, and Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Circassia, Mundipharma, Novartis, Teva Pharmaceuticals, and Thermo Fisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd., which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp, which develops an adherence monitoring technology; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. K.H. reports personal fees and non-financial support from AstraZeneca, GlaxoSmithKline, Novartis, Chiesi, Boehringer Ingelheim, Teva, Cipla, OPCA, Asthma Australia, and Spirometry Learning Australia, outside the submitted work. J.D. has nothing to disclose. S.W.T. has nothing to disclose. C.J.M. has nothing to disclose. H.K.F. is an employee of AstraZeneca. M.J.H.I.B. was an employee of AstraZeneca at the time this study was conducted.